New Biochemial marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease

P. A. Price, J. G. Parthemore, L. J. Deftos, Satoru Nishimoto

Research output: Contribution to journalArticle

549 Citations (Scopus)

Abstract

γ-Carboxyglutamic acid-containing protein of bone (BGP) is an abundant noncollagenous protein of mammalian bone. BGP has a molecular weight of 5,800 and contains three residues of the vitamin K-dependent amino acid, γ-carboxyglutamic acid. We have applied a radioimmunoassay based on calf BGP for the measurement of the protein in the plasma of 109 normal humans and 112 patients with various bone diseases. BGP in human plasma was demonstrated to be indistinguishable from calf BGP by assay dilution studies and gel permeation chromatography. The mean (±SE) concentration of BGP in normal subjects was 6.78 (±0.20) ng/ml, 7.89 (±0.32) for males and 4.85 (±0.35) for females. Plasma BGP was increased in patients with Paget's disease of bone, bone metastases, primary hyperparathyroidism, renal osteodystrophy, and osteopenia. Plasma BGP did correlate with plasma alkaline phosphatase (AP) in some instances, but there were dissociations between the two. It was additionally observed that patients with liver disease had normal plasma BGP despite increased plasma AP, a reflection of the lack of specificity of AP measurements for bone disease. Our studies indicate that the radioimmunoassay of plasma BGP can be a useful and specific procedure for evaluating the patient with bone disease.

Original languageEnglish (US)
Pages (from-to)878-883
Number of pages6
JournalJournal of Clinical Investigation
Volume66
Issue number5
DOIs
StatePublished - Jan 1 1980

Fingerprint

Bone Diseases
Radioimmunoassay
Bone and Bones
Alkaline Phosphatase
Chronic Kidney Disease-Mineral and Bone Disorder
Osteitis Deformans
Acids
Primary Hyperparathyroidism
Vitamin K
Metabolic Bone Diseases
human alpha-galactosidase A
Gel Chromatography
Liver Diseases
Blood Proteins
Proteins
Molecular Weight
Neoplasm Metastasis
Amino Acids

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

New Biochemial marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. / Price, P. A.; Parthemore, J. G.; Deftos, L. J.; Nishimoto, Satoru.

In: Journal of Clinical Investigation, Vol. 66, No. 5, 01.01.1980, p. 878-883.

Research output: Contribution to journalArticle

@article{637c68258f974243a209f0ac2e1a9058,
title = "New Biochemial marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease",
abstract = "γ-Carboxyglutamic acid-containing protein of bone (BGP) is an abundant noncollagenous protein of mammalian bone. BGP has a molecular weight of 5,800 and contains three residues of the vitamin K-dependent amino acid, γ-carboxyglutamic acid. We have applied a radioimmunoassay based on calf BGP for the measurement of the protein in the plasma of 109 normal humans and 112 patients with various bone diseases. BGP in human plasma was demonstrated to be indistinguishable from calf BGP by assay dilution studies and gel permeation chromatography. The mean (±SE) concentration of BGP in normal subjects was 6.78 (±0.20) ng/ml, 7.89 (±0.32) for males and 4.85 (±0.35) for females. Plasma BGP was increased in patients with Paget's disease of bone, bone metastases, primary hyperparathyroidism, renal osteodystrophy, and osteopenia. Plasma BGP did correlate with plasma alkaline phosphatase (AP) in some instances, but there were dissociations between the two. It was additionally observed that patients with liver disease had normal plasma BGP despite increased plasma AP, a reflection of the lack of specificity of AP measurements for bone disease. Our studies indicate that the radioimmunoassay of plasma BGP can be a useful and specific procedure for evaluating the patient with bone disease.",
author = "Price, {P. A.} and Parthemore, {J. G.} and Deftos, {L. J.} and Satoru Nishimoto",
year = "1980",
month = "1",
day = "1",
doi = "10.1172/JCI109954",
language = "English (US)",
volume = "66",
pages = "878--883",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - New Biochemial marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease

AU - Price, P. A.

AU - Parthemore, J. G.

AU - Deftos, L. J.

AU - Nishimoto, Satoru

PY - 1980/1/1

Y1 - 1980/1/1

N2 - γ-Carboxyglutamic acid-containing protein of bone (BGP) is an abundant noncollagenous protein of mammalian bone. BGP has a molecular weight of 5,800 and contains three residues of the vitamin K-dependent amino acid, γ-carboxyglutamic acid. We have applied a radioimmunoassay based on calf BGP for the measurement of the protein in the plasma of 109 normal humans and 112 patients with various bone diseases. BGP in human plasma was demonstrated to be indistinguishable from calf BGP by assay dilution studies and gel permeation chromatography. The mean (±SE) concentration of BGP in normal subjects was 6.78 (±0.20) ng/ml, 7.89 (±0.32) for males and 4.85 (±0.35) for females. Plasma BGP was increased in patients with Paget's disease of bone, bone metastases, primary hyperparathyroidism, renal osteodystrophy, and osteopenia. Plasma BGP did correlate with plasma alkaline phosphatase (AP) in some instances, but there were dissociations between the two. It was additionally observed that patients with liver disease had normal plasma BGP despite increased plasma AP, a reflection of the lack of specificity of AP measurements for bone disease. Our studies indicate that the radioimmunoassay of plasma BGP can be a useful and specific procedure for evaluating the patient with bone disease.

AB - γ-Carboxyglutamic acid-containing protein of bone (BGP) is an abundant noncollagenous protein of mammalian bone. BGP has a molecular weight of 5,800 and contains three residues of the vitamin K-dependent amino acid, γ-carboxyglutamic acid. We have applied a radioimmunoassay based on calf BGP for the measurement of the protein in the plasma of 109 normal humans and 112 patients with various bone diseases. BGP in human plasma was demonstrated to be indistinguishable from calf BGP by assay dilution studies and gel permeation chromatography. The mean (±SE) concentration of BGP in normal subjects was 6.78 (±0.20) ng/ml, 7.89 (±0.32) for males and 4.85 (±0.35) for females. Plasma BGP was increased in patients with Paget's disease of bone, bone metastases, primary hyperparathyroidism, renal osteodystrophy, and osteopenia. Plasma BGP did correlate with plasma alkaline phosphatase (AP) in some instances, but there were dissociations between the two. It was additionally observed that patients with liver disease had normal plasma BGP despite increased plasma AP, a reflection of the lack of specificity of AP measurements for bone disease. Our studies indicate that the radioimmunoassay of plasma BGP can be a useful and specific procedure for evaluating the patient with bone disease.

UR - http://www.scopus.com/inward/record.url?scp=0019226418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019226418&partnerID=8YFLogxK

U2 - 10.1172/JCI109954

DO - 10.1172/JCI109954

M3 - Article

VL - 66

SP - 878

EP - 883

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -